Short Interest in HCW Biologics Inc. (NASDAQ:HCWB) Grows By 137.9%

HCW Biologics Inc. (NASDAQ:HCWB) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 34,136 shares, an increase of 137.9% from the August 15th total of 14,348 shares. Approximately 2.0% of the company’s shares are sold short. Based on an average daily trading volume, of 238,774 shares, the days-to-cover ratio is presently 0.1 days.

HCW Biologics Stock Down 5.0%

NASDAQ:HCWB traded down $0.11 on Tuesday, reaching $2.09. 32,724 shares of the company’s stock were exchanged, compared to its average volume of 1,287,893. The firm has a market capitalization of $3.84 million, a price-to-earnings ratio of -0.08 and a beta of 2.37. The business has a fifty day moving average of $3.17 and a 200-day moving average of $4.47. HCW Biologics has a 52-week low of $1.50 and a 52-week high of $29.34.

HCW Biologics (NASDAQ:HCWB) last posted its quarterly earnings data on Friday, August 14th. The company reported ($11.58) EPS for the quarter, missing the consensus estimate of ($1.98) by ($9.60). HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%. The business had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.14 million.

Analyst Ratings Changes

HCWB has been the subject of a number of recent analyst reports. Maxim Group lifted their price target on shares of HCW Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Wall Street Zen raised shares of HCW Biologics to a “hold” rating in a research report on Saturday, May 23rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $30.00.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.